Soluble interleukin 6 receptor levels are associated with reduced myocardial reperfusion after percutaneous coronary intervention for acute myocardial infarction

Cytokine

Volumn 73, Issue 2, 2015, Pages 207-212

  Groot, Hilde E ^a   Hartman, Minke H T ^a   Gu, Youlan L ^a   de Smet, Bart J G L ^b   van den Heuvel, Ad F M ^a   Lipsic, Erik ^a   van der Harst, Pim ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Myocardial reperfusion; Soluble interleukin 6 receptor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE REPERFUSION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE COUNT; BLOOD; CASE CONTROL STUDY; ECHOGRAPHY; LEUKOCYTE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; REGRESSION ANALYSIS; SOLUBILITY; TIME;

LAKE VICTORIA MARBURGVIRUS;

C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET COUNT; RECEPTORS, INTERLEUKIN-6; REGRESSION ANALYSIS; SOLUBILITY; TIME FACTORS;

EID: 84924917622     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.02.004     Document Type: Article

References (31)

1. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17(11):1410-1422.
2. Boekholdt S.M., Stroes E.S. The interleukin-6 pathway and atherosclerosis. Lancet 2012, 379(9822):1176-1178.
3. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011, 1813(5):878-888.
4. Lexis C.P., van der Horst I.C., Lipsic E., Wieringa W.G., de Boer R.A., van den Heuvel A.F., et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA 2014, 311(15):1526-1535.
5. Zhu H., Belcher M., van der Harst P. Healthy aging and disease: role for telomere biology?. Clin Sci (Lond) 2011, 120(10):427-440.
6. Holmes M.V., Simon T., Exeter H.J., Folkersen L., Asselbergs F.W., Guardiola M., et al. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol 2013, 62(21):1966-1976.
7. Danesh J., Kaptoge S., Mann A.G., Sarwar N., Wood A., Angleman S.B., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008, 5(4):e78.
8. Emerging Risk Factors Collaboration, Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375(9709):132-140.
9. Fibrinogen Studies Collaboration, Danesh J., Lewington S., Thompson S.G., Lowe G.D., Collins R., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294(14):1799-1809.
10. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53(1):31-47.
11. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012, 8(9):1237-1247.
12. Knupfer H., Preiss R. SIL-6R: more than an agonist?. Immunol Cell Biol 2008, 86(1):87-91.
13. Karpinski L., Plaksej R., Kosmala W., Witkowska M. Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty. Kardiol Pol 2008, 66(12):1279-1285.
14. Kobara M., Noda K., Kitamura M., Okamoto A., Shiraishi T., Toba H., et al. Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc Res 2010, 87(3):424-430.
15. Nian M., Lee P., Khaper N., Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004, 94(12):1543-1553.
16. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81(4):1161-1172.
17. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Hingorani A.D., Casas J.P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012, 379(9822):1214-1224.
18. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N., Butterworth A.S., Freitag D.F., Gregson J., Willeit P., et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012, 379(9822):1205-1213.
19. Gu Y.L., Kampinga M.A., Wieringa W.G., Fokkema M.L., Nijsten M.W., Hillege H.L., et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 2010, 122(25):2709-2717.
20. Wong L.S., Huzen J., de Boer R.A., van Gilst W.H., van Veldhuisen D.J., van der Harst P. Telomere length of circulating leukocyte subpopulations and buccal cells in patients with ischemic heart failure and their offspring. PLoS One 2011, 6(8):e23118.
21. van't Hof A.W., Liem A., Suryapranata H., Hoorntje J.C., de Boer M.J., Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle myocardial infarction study group. Circulation 1998, 97(23):2302-2306.
22. Kaminski K.A., Kozuch M., Bonda T., Wojtkowska I., Kozieradzka A., Dobrzycki S., et al. Coronary sinus concentrations of interleukin 6 and its soluble receptors are affected by reperfusion and may portend complications in patients with myocardial infarction. Atherosclerosis 2009, 206(2):581-587.
23. Ueda K., Takahashi M., Ozawa K., Kinoshita M. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction. Am Heart J 1999, 138(5 Pt 1):908-915.
24. Morishima I., Sone T., Okumura K., Tsuboi H., Kondo J., Mukawa H., et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000, 36(4):1202-1209.
25. O'Regan D.P., Shi W., Ariff B., Baksi A.J., Durighel G., Rueckert D., et al. Remodeling after acute myocardial infarction: mapping ventricular dilatation using three dimensional CMR image registration. J Cardiovasc Magn Reson 2012, 14. 41-429X-14-41.
26. Ito H., Maruyama A., Iwakura K., Takiuchi S., Masuyama T., Hori M., et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996, 93(2):223-228.
27. Sezer M., Aslanger E.K., Cimen A.O., Yormaz E., Turkmen C., Umman B., et al. Concurrent microvascular and infarct remodeling after successful reperfusion of ST-elevation acute myocardial infarction. Circ Cardiovasc Interv 2010, 3(3):208-215.
28. Henriques J.P., Zijlstra F., van't Hof A.W., de Boer M.J., Dambrink J.H., Gosselink M., et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 2003, 107(16):2115-2119.
29. Blancke F., Claeys M.J., Jorens P., Vermeiren G., Bosmans J., Wuyts F.L., et al. Systemic inflammation and reperfusion injury in patients with acute myocardial infarction. Mediators Inflamm 2005, 2005(6):385-389.
30. Zhao Z.Q., Velez D.A., Wang N.P., Hewan-Lowe K.O., Nakamura M., Guyton R.A., et al. Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis 2001, 6(4):279-290.
31. Vogelzang M., Vlaar P.J., Svilaas T., Amo D., Nijsten M.W., Zijlstra F. Computer-assisted myocardial blush quantification after percutaneous coronary angioplasty for acute myocardial infarction: a substudy from the TAPAS trial. Eur Heart J 2009, 30(5):594-599.